These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 33925284)

  • 21. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy.
    Boden WE; Pearson TA
    Am J Cardiol; 2000 Mar; 85(5):645-50, A10. PubMed ID: 11078282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes.
    Viles-Gonzalez JF; Fuster V; Corti R; Badimon JJ
    Curr Opin Cardiol; 2003 Jul; 18(4):286-94. PubMed ID: 12858127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New treatment options for lipid-lowering therapy in subjects with type 2 diabetes.
    Scicali R; Di Pino A; Ferrara V; Urbano F; Piro S; Rabuazzo AM; Purrello F
    Acta Diabetol; 2018 Mar; 55(3):209-218. PubMed ID: 29260404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol].
    Brea Hernando ÁJ
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options for low high-density lipoproteins.
    Hafiane A; Kellett S; Genest J
    Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):134-9. PubMed ID: 24535232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of reverse cholesterol transport and clinical implications.
    Rader DJ
    Am J Cardiol; 2003 Aug; 92(4A):42J-49J. PubMed ID: 12957326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease.
    Estrada-Luna D; Ortiz-Rodriguez MA; Medina-Briseño L; Carreón-Torres E; Izquierdo-Vega JA; Sharma A; Cancino-Díaz JC; Pérez-Méndez O; Belefant-Miller H; Betanzos-Cabrera G
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30360466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current concept of reverse cholesterol transport and novel strategy for atheroprotection.
    Ono K
    J Cardiol; 2012 Nov; 60(5):339-43. PubMed ID: 23063661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should low high-density lipoprotein cholesterol (HDL-C) be treated?
    Toth PP; Barylski M; Nikolic D; Rizzo M; Montalto G; Banach M
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):353-68. PubMed ID: 24840264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HDL-Targeting Therapeutics: Past, Present and Future.
    Zakiev E; Feng M; Sukhorukov V; Kontush A
    Curr Pharm Des; 2017; 23(8):1207-1215. PubMed ID: 27799042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-density lipoprotein cholesterol and the role of statins.
    Chong PH; Kezele R; Franklin C
    Circ J; 2002 Nov; 66(11):1037-44. PubMed ID: 12419937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis.
    Burillo E; Andres EM; Mateo-Gallego R; Fiddyment S; Jarauta E; Cenarro A; Civeira F
    Heart; 2010 Sep; 96(17):1345-51. PubMed ID: 20801853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
    Chapman MJ
    Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease.
    Windler E; Schöffauer M; Zyriax BC
    Diab Vasc Dis Res; 2007 Jun; 4(2):136-42. PubMed ID: 17654448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of HDL in those with diabetes.
    Santos-Gallego CG; Rosenson RS
    Curr Cardiol Rep; 2014 Aug; 16(8):512. PubMed ID: 24950673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?
    Colhoun H
    Lancet; 2005 Nov; 366(9500):1829-31. PubMed ID: 16310536
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.